• Home
  • Technology
  • Pipeline
  • Partnership
  • Career
  • Team
  • Contact

Developing the Next Generation Bispecific Antibody
Drugs to Improve Cancer Treatment



Transforming Bispecific Antibody with a New Modality



⦁ We are an oncology-focused biotech company.


⦁ Using VHH antibody as a building block, we are developing novel, next generation bispecific antibody drugs to improve clinical outcome for cancer patients with resistance and/or unmet medical needs.


⦁ We focus on both immunotherapy and targeted-therapy with emphasize on bispecific antibody drug conjugates.



Contact


1230 Bordeaux Drive, Sunnyvale, CA 94089

Info@brightbiologicsllc.com



Copyright © 2020 Bright Biologics LLC - All Rights Reserved.